title: Worse or better?-Cirrhosis with hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) accounts for about 90% of all malignant tumors of liver, ranking fifth in the worldwide incidence of malignant tumors and the third in fatality. More and more evidences suggest that cancer is a metabolic-related disease. From the analysis of recent clinical research data, we found that as the severity of the cirrhosis aggravated, patients with HCC and end-stage liver cirrhosis had a flat energy metabolism which was better than it in patients with simple end-stage liver cirrhosis. Based on these clinical phenomenon, the major aim of this study is to present a new hypothesis: "compensated liver function mechanism" for patients with HCC and liver cirrhosis, cancer cells may play a role to compensate liver function. In this study, we elaborated relevant content about this novel standpoint combined with tumor energy metabolism reprogramming mechanism and tumor cell origin as well as cell exchange mechanism.
authors.affiliation: Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Ran
authors.initials: R
authors.lastname: Xue
authors.affiliation: Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, People's Republic of China. Electronic address: meng_qh@126.com.
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Meng
authors.affiliation: Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Pathology, Beijing You-An Hospital, Capital Medical University, Beijing, People's Republic of China.
authors.forename: Jiliang
authors.initials: J
authors.lastname: Feng
authors.affiliation: Aviation General Hospital of China Medical University, Beijing Institute of Translational Medicine, Chinese Academy of Sciences, People's Republic of China.
authors.forename: Hanping
authors.initials: H
authors.lastname: Shi
mesh_terms: D000818:Animals; D017209:Apoptosis; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000503:physiopathology*; D049109:Cell Proliferation; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis; D006801:Humans; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000150:complications / Q000503:physiopathology*; D009154:Mutation; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010641:Phenotype; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D005947:Glucose
keywords: Cancer cells; Cirrhosis; Energy metabolism; Hepatocellular carcinoma